Keryx Biopharmaceuticals, Inc. (KERX) EPS Estimated At $-0.16; ADM TRONICS UNLIMITED (ADMT) Shorts Increased By 85.71%

June 29, 2018 - By Linda Rogers

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Logo

Analysts expect Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report $-0.16 EPS on July, 26.They anticipate $0.05 EPS change or 23.81% from last quarter’s $-0.21 EPS. After having $-0.18 EPS previously, Keryx Biopharmaceuticals, Inc.’s analysts see -11.11% EPS growth. The stock increased 0.96% or $0.03 during the last trading session, reaching $3.66. About 1.44M shares traded or 17.93% up from the average. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 18.22% since June 29, 2017 and is downtrending. It has underperformed by 30.79% the S&P500. Some Historical KERX News: 29/05/2018 – Keryx Pharmaceuticals Announces Upcoming Investor Presentations; 08/05/2018 – The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes it; 24/05/2018 – Keryx Presenting at ERA-EDTA Annual Congress 2018 Tomorrow; 10/05/2018 – Keryx Biopharmaceuticals: Certain Investment Partnerships Advised by Baupost Group Agreed to Exchange Notes and Cash for New Note; 11/04/2018 – Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation; 13/04/2018 – Keryx’s Auryxia Retail Sales Rose 0.2% in Latest Week: Symphony; 07/05/2018 – Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2018 Financial Results on Thursday, May 10, 2018; 25/05/2018 – KERYX BIOPHARMACEUTICALS ANNOUNCES DATA FROM AN INVESTIGATOR SPONSORED TRIAL OF FERRIC CITRATE IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE IN A LATE-BREAKING PRESENTATION AT THE 55TH ANNUAL…; 04/04/2018 – KERYX BIOPHARMACEUTICALS ANNOUNCES PUBLICATION OF DATA FROM THE PHASE 3 TRIAL OF AURYXIA® (FERRIC CITRATE) FOR IRON DEFICIENCY ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE, NOT ON DIALYSIS, IN THE…; 11/04/2018 – Keryx Closes Above 50-Day Moving Average: Technicals

ADM TRONICS UNLIMITED INC (OTCMKTS:ADMT) had an increase of 85.71% in short interest. ADMT’s SI was 9,100 shares in June as released by FINRA. Its up 85.71% from 4,900 shares previously. With 27,000 avg volume, 0 days are for ADM TRONICS UNLIMITED INC (OTCMKTS:ADMT)’s short sellers to cover ADMT’s short positions. The SI to ADM TRONICS UNLIMITED INC’s float is 0.02%. It closed at $0.17 lastly. It is down 0.00% since June 29, 2017 and is . It has underperformed by 12.57% the S&P500.

ADM Tronics Unlimited, Inc. primarily develops and makes electronics for non-invasive medical and other applications in the United States, Australia, Asia, and Europe. The company has market cap of $11.49 million. The firm offers proprietary devices for use in diagnostics and therapeutics of humans and animals; electronic controllers for spas and hot tubs; and Sonotron Technology, a technology to treat subjects suffering from the pain of inflammatory joint conditions. It has a 34 P/E ratio. It also provides water primers and adhesives; water coatings and resins; water chemical additives; and anti-static conductive paints, coatings, and other products.

Among 4 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Keryx Biopharmaceuticals had 4 analyst reports since February 8, 2018 according to SRatingsIntel. The company was downgraded on Thursday, June 28 by Maxim Group. Morgan Stanley maintained the shares of KERX in report on Thursday, February 8 with “Equal-Weight” rating.

More notable recent Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) news were published by: Seekingalpha.com which released: “Akebia Therapeutics, Keryx Biopharma agree to merge” on June 28, 2018, also Nasdaq.com with their article: “Mid-Afternoon Market Update: Dow Rises Over 100 Points; Progress Software Shares Spike Higher” published on June 28, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos” on June 29, 2018. More interesting news about Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) were released by: Benzinga.com and their article: “48 Biggest Movers From Yesterday” published on June 29, 2018 as well as 247Wallst.com‘s news article titled: “Walgreens, Starbucks Straggle into Thursday’s 52-Week Low Club” with publication date: June 28, 2018.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $441.73 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

Since January 5, 2018, it had 0 insider buys, and 21 selling transactions for $318,991 activity. Adams Brian sold $7,412 worth of stock. Neylan John F. had sold 1,111 shares worth $5,099. Holmes Scott A sold $6,589 worth of stock. Another trade for 1,334 shares valued at $6,830 was made by GILMAN STEVEN C on Monday, June 11. $9,786 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was sold by Carberry Christine A. on Wednesday, April 18. Another trade for 1,067 shares valued at $5,004 was made by Madison Greg on Friday, January 5. $8,302 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) shares were sold by Cameron Kevin J.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.